Let's talk medical research

Primary biliary cholangitis (PBC) is an autoimmune condition that causes progressive destruction of the bile ducts. Current treatment options focus on delaying progression and managing complications, but it can be difficult to live with the symptoms, like fatigue, itchy skin, and pain, as well.

Last week, Antidote’s Head of Partnerships, Lindsey Wahlstrom-Edwards, hosted a webinar in which she shared the results of our patient survey. In the survey, we asked nearly 4,000 patients and caregivers about their attitudes and opinions of clinical research to find out what matters most, and how we can better engage patients from all walks of life in medical research.

Recently, Antidote’s Director of Business Development, Rachel Lind, was featured on the fantastic ERT podcast, “Trial Better.” She and host Jason Eger, Director of Organizational Readiness at ERT, discussed the changing landscape of patient recruitment, the ways in which patients are becoming their own advocates, the importance of diversity in clinical trials, and reducing site burden through ...

In 2014, Stacy Hurt was enjoying a booming career in the pharmaceutical company and life with her husband and eight- and ten-year-old sons. Though Stacy's life was not easy – her youngest son has, in her words, "profound disabilities", and requires around the clock care – her family was thriving.

October is Health Literacy Month. Health literacy refers to how well patients understand medical information from doctors. It plays a critical role in whether or not a patient receives the right care for them.

It’s no secret that recruiting patients for clinical trials can be a difficult endeavor. And, even when a trial meets its quotas and timelines, many still do not reflect real-world populations. So how can we better engage patients from all walks of life in medical research?

Of all of the elements of a clinical trial, optimizing patient recruitment may make the most significant impact on trial timelines. Even if you're meeting your recruitment goals – a rare accomplishment, to say the least – trials and budgets always benefit from better efficiency.

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation.

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series.